Relief Therapeutics (OTC: RLFTF) has been in the news for quite some time due to its work in collaboration with NeuroRx on the product Aviptadil, which is meant for treating COVID 19 patients.
On Friday, the Relief stock was on the move and managed to jump by 8%. While it is true that there was no news with regards to the company on Friday, it might be a good idea to take a look at development from earlier on this month.
It was announced that Aviptadil was one of the two products that were selected by the National Institutes of Health that are going to be part of a Phase III multicenter clinical trial. The trial is going to include the United States and many other nations. It goes without saying that it is a significant development for Relief Therapeutics. It now remains to be seen if the stock can continue to hold on to its momentum this week.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.